Antipsychotic dopamine D

Antipsychotic medication Dopamine D(2) affinity First episode psychosis Negative symptoms

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
18 Oct 2024
Historique:
received: 07 05 2024
revised: 26 08 2024
accepted: 27 09 2024
medline: 19 10 2024
pubmed: 19 10 2024
entrez: 19 10 2024
Statut: aheadofprint

Résumé

Negative symptoms can be an integral part of schizophrenia spectrum pathology and can be secondary to other psychotic symptoms or caused by antipsychotic medication. As antipsychotic drugs differ in their affinity to dopamine receptors and some antipsychotics have partial agonistic effects, antipsychotic drugs are expected to vary in their ability to cause negative symptoms. The association between negative symptoms and antipsychotic medication divided into partial agonists, or antagonists with high or low D

Identifiants

DOI: 10.1016/j.schres.2024.09.030 PMID: 39426016
pubmed: 39426016
pii: S0920-9964(24)00439-0
doi: 10.1016/j.schres.2024.09.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-306

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest F.B., B.W., L.W., S.K., S.G., W.V., N.B., L.H., M.B. report no financial relationships with commercial interest. I.S. participates in a trial from Boehringer-Ingelheim, has received speakers' fee from Otsuka, and a charity grant from Janssen.

Auteurs

Franciska de Beer (F)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands. Electronic address: f.de.beer@umcg.nl.

Ben Wijnen (B)

Centre of Economic Evaluations & Machine Learning, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands.

Lotte Wouda (L)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands.

Sanne Koops (S)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands.

Shiral Gangadin (S)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.

Wim Veling (W)

University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.

Nico van Beveren (N)

Parnassia Group for Mental Health Care, The Hague, the Netherlands; Department of Neuroscience, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Psychiatry, Erasmus Medical Centre, Rotterdam, the Netherlands.

Lieuwe de Haan (L)

Amsterdam University Medical Centre, University of Amsterdam, Department of Psychiatry, Amsterdam, the Netherlands; Arkin, Institute for Mental Health, Amsterdam, the Netherlands.

Marieke J H Begemann (MJH)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands.

Iris E C Sommer (IEC)

University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.

Classifications MeSH